Bug Gesine, Schwarz Kerstin, Schoch Claudia, Kampfmann Manuela, Henschler Reinhard, Hoelzer Dieter, Ottmann Oliver G, Ruthardt Martin
Medizinische Klinik II, Abt. Hämatologie/Onkologie, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Theodor-Stern-Kai 7, Frankfurt, Germany.
Haematologica. 2007 Apr;92(4):542-5. doi: 10.3324/haematol.10758.
Histone deacetylase inhibitor valproic acid (VPA) was recently shown to enhance proliferation and self-renewal of normal hematopoietic stem cells, raising the possibility that VPA may also support growth of leukemic progenitor cells (LPC). Here, VPA maintains a significantly higher proportion of CD34+ LPC and colony forming units compared to control cultures in six AML samples, but selectively reduces leukemic cell numbers in another AML sample with expression of AML1/ETO. Our data suggest a differential effect of VPA on the small population of AML progenitor cells and the bulk of aberrantly differentiated blasts in the majority of AML samples tested.
组蛋白去乙酰化酶抑制剂丙戊酸(VPA)最近被证明可增强正常造血干细胞的增殖和自我更新能力,这增加了VPA也可能支持白血病祖细胞(LPC)生长的可能性。在此,与六个急性髓系白血病(AML)样本中的对照培养物相比,VPA可维持更高比例的CD34 + LPC和集落形成单位,但在另一个表达AML1/ETO的AML样本中可选择性地减少白血病细胞数量。我们的数据表明,在大多数测试的AML样本中,VPA对一小部分AML祖细胞和大部分异常分化的母细胞有不同的作用。